Tasimelteon: A Novel Melatonin Receptor Agonist for Circadian Rhythm Disorders
Experience regulated sleep cycles with Tasimelteon, a selective melatonin receptor agonist.
Get a Quote & SampleProduct Core Value
Tasimelteon
Tasimelteon is a selective dual agonist of the melatonin receptors MT1 and MT2, playing a crucial role in regulating circadian rhythms. This makes it an effective treatment for conditions like Non-24-Hour Sleep-Wake Disorder (Non-24HSWD), particularly in individuals without light perception. By targeting these receptors, tasimelteon helps to resynchronize the body's internal clock.
- Discover how tasimelteon's unique receptor binding profile distinguishes it from other melatonin receptor agonists, offering a targeted approach to sleep disorder treatment.
- Explore the therapeutic potential of tasimelteon for Smith-Magenis Syndrome, addressing nighttime sleep disturbances in affected individuals.
- Understand the mechanism of action for tasimelteon as a Melatonin Receptor Agonist and its impact on the suprachiasmatic nucleus.
- Learn about the development and FDA approval of tasimelteon for Non-24HSWD, highlighting its significance as a therapeutic option.
Key Advantages
Selective Melatonin Receptor Activation
Tasimelteon selectively targets MT1 and MT2 melatonin receptors, providing a precise mechanism to influence circadian rhythms and improve sleep patterns, which is vital for individuals dealing with Non-24HSWD.
Treatment for Sleep Disturbances
This compound is specifically indicated for treating nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), offering a solution for a challenging condition where circadian rhythm disorders are prevalent.
FDA Approved for Specific Conditions
With FDA approval for indications such as Non-24-Hour Sleep-Wake Disorder, Tasimelteon provides a trusted and clinically validated treatment option for patients seeking to regulate their sleep-wake cycles.
Key Applications
Non-24-Hour Sleep-Wake Disorder (Non-24HSWD)
Tasimelteon is a primary treatment for Non-24HSWD, a disorder often affecting blind individuals by disrupting their internal body clock. Its use helps re-establish a normal sleep-wake cycle, enhancing overall quality of life.
Smith-Magenis Syndrome (SMS) Sleep Disturbances
The drug addresses nighttime sleep issues associated with Smith-Magenis Syndrome, a genetic disorder that can lead to significant behavioral and developmental challenges, including disrupted sleep patterns.
Circadian Rhythm Regulation
As a potent melatonin receptor agonist, tasimelteon is fundamental in regulating the body's natural 24-hour cycles, offering a solution for various conditions where circadian rhythm is misaligned.
Pharmaceutical Research and Development
Tasimelteon serves as a key compound in ongoing research for sleep disorders and related neurological conditions, contributing to the advancement of treatments in pharmaceutical chemicals.
Related Technical Articles & Resources
Why Choose Us?
Leverage our expertise and state-of-the-art infrastructure to accelerate your journey from discovery to commercial success.
Global Experience
With 20 years of R&D, manufacturing, and sales experience, we proudly serve clients across 60 countries and regions worldwide.
Advanced Facilities
Our in-house R&D laboratory, pilot platform, and large-scale production workshop are equipped to meet the audit requirements of global customers.
Seamless Scalability
We facilitate a perfect transition from small-scale lab requirements (grams) to full commercialization (hundreds of tons).